Net Income (USD, millions)

Depreciation and Amortization (USD, millions)

Share-Based Compensation (USD, millions)

Deferred Taxes Expense (Benefit) (USD, millions)

Excess and Obsolete Inventory Related Charges (USD, millions)

Net (Gain) Loss on Equity Securities (USD, millions)

Asset Impairment Charges (USD, millions)

Change in Fair Value of Contingent Consideration (USD, millions)

Loss on Extinguishment of Debt (USD, millions)

Other Non-Cash (Income) Expense, Net (USD, millions)

Employee Compensation and Benefits (USD, millions)

Net Cash Provided by Operating Activities (USD, millions)

Payments to Acquire Property, Plant and Equipment (USD, millions)

Proceeds from Sale of Equity Securities (USD, millions)

Payments to Acquire Equity Securities (USD, millions)

Payment in Exchange for Convertible Note (USD, millions)

Payments to Acquire Businesses and Intangible Assets, Net of Cash Acquired (USD, millions)

Net Cash Used in Investing Activities (USD, millions)

Proceeds from Issuance of Common Stock Under Employee Stock Plans (USD, millions)

Payment of Taxes Related to Net Share Settlement of Equity Awards (USD, millions)

Payments for Repurchase of Common Stock (USD, millions)

Payment of Excise Taxes Related to Repurchases of Common Stock (USD, millions)

Payment of Dividends (USD, millions)

Proceeds from Issuance of Long-Term Debt (USD, millions)

Repayment of Long-Term Debt (USD, millions)

Payments of Debt Issuance Costs (USD, millions)

Net Proceeds from (Repayments of) Short Term Debt (USD, millions)

Net Cash Used in Financing Activities (USD, millions)

Effect of Exchange Rate Movements (USD, millions)

Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash (USD, millions)

Income Tax Payments, Net of Refunds Received (USD, millions)

Interest Payments, Net of Capitalized Interest (USD, millions)

Net Change in Property, Plant and Equipment Included in Accounts Payable and Accrued Liabilities-Increase (Decrease) (USD, millions)

Accounts Receivable, Net (USD, millions)

Inventory (USD, millions)

Accounts Payable (USD, millions)

Other Assets and Liabilities (USD, millions)

Cash, Cash Equivalents and Restricted Cash at Beginning of Year (USD, millions)

Cash, Cash Equivalents and Restricted Cash at End of Year (USD, millions)

Excise Tax on Share Repurchases, Accrued but Not Paid (USD, millions)

f3698b67dbf1f6da8143b7391bc83624db5b596b7c9e000855f6fdb23d35b393

The documents indicate that no single definitive reason is provided for the lower cash balance in Q4 2024. However, several financial activities likely contributed to the reduction in cash and cash equivalents to **$1,329 million**. These include **capital expenditures of $93 million**, over **$400 million** in shareholder returns (including **$335 million** in share repurchases and **$68 million** in dividends), and the acquisition of BIOVECTRA, even though the company generated a strong operating cash flow of **$1.75 billion**. These activities collectively could explain why the cash reserve was lower during that period.  **[0001090872-24-000049_a-20241031.htm:91]** **[0001090872-24-000042_exhibit991-q424pressrelease.htm:4]** **[A_3409990_5]** 

Why was Cash and cash equivalents so low in Q4 2024?

The sharp increase in total assets in Q4 2024 was driven by strategic acquisitions and investments. **Goodwill** saw a notable rise, primarily due to the BIOVECTRA acquisition, which added **$526 million** to goodwill, while **property, plant, and equipment, other assets, and other intangible assets** also experienced significant increases that collectively boosted the total asset value.  **[0001090872-24-000049_a-20241031.htm:91]** **[0001090872-24-000049_a-20241031.htm:130]** 

What drove the sharp increase in Total assets in Q4 2024?

The jump in **long-term debt** during Q4 2024 was driven by several factors. Specifically, the company issued **$600 million of 2027 Senior Notes at a 4.20% interest rate** and **$600 million of 2034 Senior Notes at a 4.75% interest rate**, repaid **$600 million of its term loan facility**, and assumed **$18 million and $1 million in long-term debt** related to the BIOVECTRA acquisition. These actions collectively resulted in a net increase of **$610 million** compared to the previous year.  **[0001090872-24-000049_a-20241031.htm:83]** **[0001090872-24-000049_a-20241031.htm:154]** 

What caused the sudden jump in Long-term debt in Q4 2024?

d94dd48c971fb68a52ee6806901070503144f17e45fb9906b1e2b88fb7d5a085

The **Net Revenue - Products** decline in **FY 2024** occurred mainly due to **customer capital expenditure pressures**—notably in the **pharmaceutical market** affecting the **life sciences**, **applied**, and **diagnostics & genomics** segments—as well as **weakness in key product lines** such as **Liquid Chromatography (LC)**, **Mass Spectrometry (MS)**, **Cell Analysis**, and **Nucleic Acid Solutions**. Additionally, there was **geographic weakness** (especially in the **Americas** and **Asia Pacific, including China**) and, while there was some offset from **growth in consumables and pathology businesses**, the overall effect was a **7% decline** in product revenue. Foreign currency movements, however, did not impact the revenue growth.  **[0001090872-24-000049_a-20241031.htm:66]** **[0001090872-24-000049_a-20241031.htm:67]** 

Why did Net Revenue - Products drop in FY 2024?

The significant **EPS jump** in Q3 2024 was driven by several factors. Firstly, **net income increased** dramatically from **$111 million** in Q3 2023 to **$282 million** in Q3 2024, boosting the net income per share from **$0.38** to **$0.97**. Additionally, **effective cost management** and **operational efficiency improvements** helped offset a decline in revenue, contributing to better margins. Lastly, **strategic transformation initiatives** and **investments in growth opportunities** enhanced operational performance, further driving the EPS increase.  **[0001090872-24-000024_exhibit991-q324pressrelease.htm:4]** **[0001090872-24-000033_a-20240731.htm:1]** 

What factors drove the EPS jump in Q3 2024?

Income from Operations in Q3 2024 is significantly higher primarily because of a combination of **restructuring charges** that positively impacted the period, alongside a relative absence of the adverse **asset impairment charges** that affected Q3 2023. Additionally, there was a boost from higher **interest income** (rising from **$13 million** to **$19 million**) due to increased cash balances and higher rates, and effective **cost management** helped reduce expenses, contributing to the overall gain of **$200 million or 151%** over Q3 2023.  **[0001090872-24-000033_a-20240731.htm:49]** **[0001090872-24-000033_a-20240731.htm:54]** **[0001090872-24-000033_a-20240731.htm:48]** 

Why is Income from Operations much higher in Q3 2024?

The tax provision turned positive in Q4 2024 because the company experienced a significant increase in its effective tax rate—from **7.4%** in Q4 2023 to **15.3%** in Q4 2024. This change was largely due to the elimination of a sizable federal tax benefit stemming from a realized loss on a divestiture, which had previously contributed to a tax benefit in 2023. In addition, the impact of a **$47 million** tax benefit related to foreign-derived intangible income and a less favorable adjustment in the Singapore tax holiday—where the benefit decreased compared to the prior period—further contributed to turning the tax treatment from a benefit to a positive provision.  **[0001090872-24-000049_a-20241031.htm:124]** **[0001090872-24-000049_a-20241031.htm:71]** 

What caused the tax provision to turn positive in Q4 2024?

1c50c401d75608b918ee031f8a0c22983ed527c348f3a07e093db9b1808f1cfb

Cash and cash equivalents (USD, millions)

Accounts receivable, net (USD, millions)

Other current assets (USD, millions)

Total current assets (USD, millions)

Property, plant and equipment, net (USD, millions)

Goodwill (USD, millions)

Other intangible assets, net (USD, millions)

Long-term investments (USD, millions)

Other assets (USD, millions)

Total assets (USD, millions)

Accounts payable (USD, millions)

Employee compensation and benefits (USD, millions)

Deferred revenue (USD, millions)

Short-term debt (USD, millions)

Other accrued liabilities (USD, millions)

Total current liabilities (USD, millions)

Long-term debt (USD, millions)

Retirement and post-retirement benefits (USD, millions)

Other long-term liabilities (USD, millions)

Total liabilities (USD, millions)

Common stock (USD, millions)

Additional paid-in-capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total stockholders' equity (USD, millions)

Total liabilities and stockholders' equity (USD, millions)

dbad5ec350f5cf976f2911484cb6d11e58a08d2c6f47461d6117aa745edd8c9c

Total Net Revenue (USD, millions)

Total Costs (USD, millions)

Research and Development (USD, millions)

Selling, General and Administrative (USD, millions)

Total Costs and Expenses (USD, millions)

Income from Operations (USD, millions)

Interest Income (USD, millions)

Interest Expense (USD, millions)

Other Income (Expense), Net (USD, millions)

Income Before Taxes (USD, millions)

Provision for Income Taxes (USD, millions)

Net Income per Share - Basic (USD)

Net Income per Share - Diluted (USD)

Weighted Average Shares Used in Computing Net Income per Share - Basic (millions)

Weighted Average Shares Used in Computing Net Income per Share - Diluted (millions)

129ceea4a679d265ad87b158bbcbac13a5ae67e7bef0ec0f58aaac7da5130998

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

Selling, General, and Administrative Expenses (SG&A) [USD, Millions]

Research and Development (R&D) [USD, Millions]

Depreciation and Amortization (D&A) [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

Earnings Per Share (EPS) - Basic [USD]

Earnings Per Share (EPS) - Diluted [USD]

aa94b6ee4a07a0fe2fb726f1131b373df34813659d36015ec314b09e3658bf67

Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from / Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

e744ecdd5709ab4e85e430d2f45e8e33d5a2b7ed21269f07c949b568fb8cd2ef

1882e74f6b2dc675b94e5cb0b2aaa54e9198776841b1558fcac2f457e6b57f6d

Days sales outstanding (days)

Inventory days on-hand (days)

17a8a9d00312400f38a481cbc56ebf2296460c9bd398369d7127cb65576965fc

Americas

Europe

Asia Pacific

- United States

- China including Hong Kong

- Rest of the World

Total Revenue

2a2db731c2898458cfa4c50d358f712fc75a16402a82a4b65c9362fb14e614b4

Life Sciences and Applied Markets

Diagnostics and Genomics

Agilent CrossLab

- Products

- Services and Other

- Analytical Lab Consumables

- Diagnostics and Genomics Solutions

- Informatics and Other

Life Sciences and Diagnostics Markets Group (LDG)

Applied Markets Group (AMG)

92fd0169c6ae58ba4e38830f12e68ff0386362166ea1220d816ca7a24110ba95

AGILENT TECHNOLOGIES (A)

Financials